Group 1 - The investment rating for the company is not explicitly stated in the provided documents [1] - The core viewpoint of the report highlights that the company is a leading semiconductor third-party testing enterprise in China, often referred to as the "chip general hospital" [1][9] - The company has achieved a compound annual growth rate (CAGR) of 35% in revenue and 43% in net profit from 2021 to 2024, with a market share of 7.86% in failure analysis and material analysis in 2023 [1][13][35] Group 2 - The semiconductor third-party testing industry is experiencing growth driven by rapid technological iterations, domestic industrialization, and increased process tolerance requirements [2][33] - The market for third-party laboratory testing is expected to reach 180-200 billion yuan in China by 2027, with a global market size projected to reach 6.677 billion USD [35][36] - The industry is characterized by a fragmented competitive landscape, but leading companies are expected to benefit significantly from the growth in demand and the deepening of the Labless model [2][40] Group 3 - The company has a strong technical capability, covering advanced process testing down to 3nm, and serves over 2,000 global clients, including major semiconductor firms like Qualcomm and Broadcom [3][9] - The company focuses on high-margin services such as failure analysis (FA) and material analysis (MA), which accounted for 97.09% of its revenue in the first half of 2024 [10][44] - The company maintains a high gross margin of 46.86% in 2024, supported by a robust revenue structure and effective cost management [13][24]
胜科纳米（688757）：国内领先的半导体第三方检测企业，失效与材料分析领军者